A selection of Lancet research highlights from July 25, 2020.

!----Enquatabina used noofovir amine for HIV infection prevention DOI in high-risk populations: For HIV patients, the fenofoviraphenol amine is more advantageous in terms of antiviral effects and improved kidney and bone safetyRecently, researchers compared the efficacy and safety of Enquala-Benaitan with direolinor or eiraphenol amine for HIV exposure prevention (PrEP)5387 participants, of whom 2,694 were noofovir amine and 2,693 were for Nofovir difuranAll participants completed 48 weeks of follow-up and 50% of the participants completed 96 weeks of follow-up, and the results showed no significant difference in the prevention of HIV infection compared to tenofovir dithofane, reaching a non-inferior endpointAfter 8,756 follow-ups, 22 participants were diagnosed with HIV, of which 7 were in the Alarphenol group (0.16 cases of infection/100 people-years) and 15 in the diofan group (0.34 cases/100 people-years)Both treatmentoptions were well tolerated, and few participants reported suspension due to adverse eventsIn all six pre-specified bone density and kidney biomarker safety endpoints, tenofoviraphenol was superior to dillin2Abrocitinib single drug for the treatment of moderate-severe adhesion dermatitis treatment DOI: Abrocitinib is an oral selective Janus kinase 1 inhibitor, recently researchers assessed the effectiveness and safety of Abrocitinib single drug treatment in adolescents and adults of moderate-to-severe atopic dermatitisIN THE JADE MONO-1 STUDY, PATIENTS OVER 12 YEARS OF AGE WITH MODERATE TO SEVERE ADHESION DERMATITIS WERE RANDOMLY TREATED WITH 100 MG, 200 MG OF ABROCITINIB OR PLACEBO, ONCE DAILY FOR 12 WEEKSThe common endpoint is the proportion of patients who received an overall assessment response (defined as a score of 0 (cleared) or 1 (almost cleared) and an improvement of 2 degrees over the baseline) and a rate of at least 75% higher than the baseline in the EASI-75 score156 patients received 100 mg of abrocitinib treatment, 154 patients received 200 mg of abrocitinib treatment and 77 patients received a placeboAt the 12th week, the proportion of patients in the 100 mg abrocitinib group who achieved the overall assessment response was significantly higher than in the placebo group (6 out of 156 patients vs 76), and the proportion of patients in the abrocitinib 200 mg group who achieved the overall assessment response was significantly higher than the placebo group (6 out of 67 vs 76 patients in 153 patients)In week 12, the proportion of patients in the abrocitinib 100 mg group (62/156 vs 9/76) and the abrocitinib 200 mg group (96/153 vs 9/76) received a significantly higher response from EASI-75 than the placebo group in week 12The difference in the rate of adverse events between groups was not significant3 Maintaining low-dose glucocorticoid therapy for symptom control doDI in patients with rheumatoid arthritis: Rheumatoid arthritis can produce a variety of adverse effects due to the long-term use of glucocorticoid drugs, and researchers recently examined the effectiveness of a gradual reduction of oral glucocorticoid syrosotrophic regimetosis for the treatment of rheumatoid arthritis In the SEMIRA study, patients with stable symptoms after treatment with toluride monotomare and a small dose of glucocorticoids (polynisone 5mg) had a disease activity score of no more than 3.2 for 28 joints in the first 4-6 weeks and the day before the grouping The above patients were randomly treated with continuous penisone 5 mg/day for 24 weeks, or gradually reduced their dosage at the 16th week until the drug was discontinued The main result of the study was differences in the changes in the average DAS28-ESR from the baseline check to the 24th week The study found that in 128 patients who received the maintenance-based persisone programme, the active control effect of the disease was better than that of 131 patients who received the persisone reduction programme: the peri-prevarisuson reduction programme group from baseline examination to 24 weeks, the estimated average change of DAS28-ESR was 0.54, and the pernicent maintenance programme group was -0.08 The treatment was successful in 99 patients in the persinisone maintenance group (defined as 24 weeks of low disease activity, with no rheumatoid arthritis attacks at 24 weeks, and no confirmed adrenal insufficiency), while 85 patients in the perinatum reduction group were successful (relative risk 0.83) In 7 patients in the pertinisone reduction group, there were severe adverse events, and 4 cases of pernison maintenance group (5 vs 3%), none of the patients developed symptomatic adrenal insufficiency Source: MedSci Original !-- Content Presentation Ends - !-- Determine Signed-Down.